Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies - Additional Information (Details)

v3.21.1
Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)
 12 Months Ended
Jan. 03, 2020
Oct. 02, 2019
Feb. 21, 2017
Jul. 09, 2015
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2016
Restricted Cash and Cash Equivalents, Noncurrent         $ 45,000 $ 45,000  
Goodwill         3,484,607 1,525,896  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles         9,536,414 3,912,314  
Intangible Assets And In process Research And Development         193,750 218,750  
Deferred Tax Liabilities, Net         $ 728,926 $ 365,364  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number         77,262 50,187  
Payments for manufacturing services         $ 502,000 $ 192,000  
Payments to Clinical Trial Services           978,000  
Class Of Warrant Or Right Number Of Warrant Issued   600,000          
Stock Issued During Period, Shares, New Issues 500,000 600,000          
Share Purchase Price Of Common Stock And Warrant   $ 3.125          
Proceeds from Issuance of Private Placement $ 5.0 $ 1,800,000     1,800,000    
Money Market Funds Fair Value         5,342,950 1,710,000  
Contingent Consideration Funds Fair Value           500,000  
Other assets or liabilities that are subject to fair value methodology and estimation         0 $ 0  
Contract with Customer, Liability, Revenue Recognized         $ 2,686,000    
Maximum [Member]              
Property, Plant and Equipment, Useful Life         5 years    
Minimum [Member]              
Property, Plant and Equipment, Useful Life         2 years    
New Valeant Agreement              
Proceeds From Upfront Payment     $ 4,000,000 $ 1,000,000      
Contract with Customer, Liability, Revenue Recognized     99,000,000 32,500,000      
Revenue Recognition Milestone Payments     $ 3,400,000 $ 5,400,000      
Panoptes acquisition              
Addition earn-out Fair value         $ 3,632,950    
Contingent consideration         $ 9,500,000    
Jade acquisition              
Addition earn-out Fair value             $ 1,210,000
Contingent consideration             $ 2,164,451